Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: nord who wrote (5491)	10/13/1998 7:42:00 PM
From: billkirn	Read Replies (1) \| Respond to of 6136

Nord: Great information "According to Credit Suisse First Boston analysts, Viracept is the best-selling AIDS treatment of its kind (protease inhibitor) in Europe". Not sure why the stock is performing so poorly today but I still think 1999 will be an excellent year. ValueLine is now tracking the stock and has a positive rating for it I hear. Bill

To: nord who wrote (5491)	10/14/1998 10:38:00 AM
From: John Romeo	Read Replies (1) \| Respond to of 6136

I find it interesting Roche has it's own PI and can sell AGPH at the same time, aren't there conflicts of interests.Also how Roche tried to screw AGPH on the oncology biz by dropping one and wanting to pick and choose which cancer drug they wanted to continue with. Versus their original agreement. AGPH showed strong backbone and told them all or none. It just seems like odd bedfellows, also with fotorvase being a bid. PI. Would there be a clear conflict when Viracept gets bid, approval.